Navigation Links
Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
Date:2/13/2008

NEW YORK, Feb. 13 /PRNewswire/ -- Today, more than ever before, pharmaceutical sales and marketing executives are facing challenges from all sides. Internally, the pressure to fill pipelines, demands for more R&D results, and competition from generics demand new outcomes from pharmaceutical marketing and sales teams across the board.

Externally, new U.S.-based regulatory (e.g. post-approval monitoring), legislative, and patent issues continue to loom. Changes affecting the sales and marketing functions of the industry are inevitable as a new administration takes control of the FDA, FTC and other agencies in 2009.

International Institute for Business Information & Growth (iiBIG) presents the 2nd Annual Pharmaceutical Sales & Marketing Executive Congress, scheduled for March 31 - April 1, 2008 in Bethesda, Maryland. This year's conference will outline trends, case studies, and best-practices required to reformulate pharmaceutical marketing and sales strategies in the light of the new rules of engagement. Two new speakers to join our speaking faculty are:

-- Adriane Fugh-Berman MD, Associate Professor, Complementary and

Alternative Medicine Masters Program, Department of Physiology and

Biophysics, Georgetown University

Dr. Fugh-Berman will discuss important developments from the physician side and how physicians are responding to some irregular and wrong practices in pharma CME.

-- Lori Ryan, Executive Director, Head of Finance CVM Sales Force,

Novartis Pharmaceuticals

Ms. Ryan joins our panel on the State of the Industry - Challenges & Opportunities in 2008 and Beyond, joining distinguished faculty from Best Practices, Jazz Pharmaceuticals, and Scientific Advantage.

Dr. Fugh-Berman and Ms. Ryan joins top industry leaders in this field including Hon. Gene Green (D-TX), Member, Health Subcommittee - Energy & Commerce Committee, U. S. House of Representatives; Paul J. Savidge, VP, Global Labeling & Compliance, Bristol-Myers Squibb; Liliana A. Gil, Worldwide Director of Marketing Services & Hispanic Strategy Lead, Johnson & Johnson; and Ellen Shapiro, Director, Division of Communications, Center for Drug Evaluation and Research (CDER), FDA.

This year's agenda will review the latest developments - legislative and otherwise - from Capitol Hill to burgeoning competition to missed opportunities affecting Big Pharma's marketing, sales, and compliance efforts for market dominance.

For Conference Updates and Speaker Roster: http://www.iibig.com/P0802.


'/>"/>
SOURCE iiBIG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Healing Our Land, Inc. and The Massachusetts Black Legislative Caucus Convene Prevention Is Power Community Forum on the Impact of HIV/AIDS on Communities of Color in Massachusetts
2. MichBio Announces Formation of Biotechnology Legislative Caucus
3. Hospital-led Coalition Cautions Motorists on New Risks October 1, Lauds Legislative Leaders for Scheduling No-fault Hearings Next Week
4. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
5. AHCA: Rescinding $2.7 Billion Medicare Cuts Top Issue for Fall Legislative Agenda
6. Cipher provides CIP-TRAMADOL ER regulatory update
7. Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements
8. Mannatech Names New VP of Regulatory Affairs, Quality Assurance
9. Cardiome And Astellas Announce Regulatory Update
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... is poised to once again host, Swirl, A Wine Tasting Event at the ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
(Date:2/5/2016)... ... 2016 , ... Boar’s Head Brand®, one of the nation’s leading providers of ... Take the stress out of your party preparation – follow these easy, yet delicious ... of the game. , “The key to hosting a successful game-day party is creating ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... 2016 In response to the opioid abuse epidemic, ... for Medical Products and Tobacco, along with other FDA leaders, ... approach to opioid medications. The plan will focus on policies ... pain access to effective relief. --> ... Re-examine the risk-benefit paradigm for opioids and ensure that the ...
Breaking Medicine Technology: